Clinical Trial Update: Treatment of Covid-19 Associated Pneumonia With Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluating allogenic pooled olfactory mucosa-derived mesenchymal stem cells for treatment of COVID-19 associated pneumonia has been c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumonia Interstitial
• Pneumonia Viral

Drugs mentioned

• Allogenic pooled olfactory mucosa-derived mesenchymal stem cells (mesenchymal stem cells)

Snippet

Sponsor: Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus | Conditions: COVID, Covid-19 | Phase 1, Phase 2 | Status: COMPLETED